Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Notes Payables (2016)

United Therapeutics (UTHR) has disclosed Notes Payables for 8 consecutive years, with $900000.0 as the latest value for Q2 2016.

  • Quarterly Notes Payables fell 97.21% to $900000.0 in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $900000.0 through Jun 2016, down 97.21% year-over-year, with the annual reading at $5.4 million for FY2015, 95.73% down from the prior year.
  • Notes Payables hit $900000.0 in Q2 2016 for United Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $224.7 million in Q3 2014 to a low of $900000.0 in Q2 2016.
  • Historically, Notes Payables has averaged $104.9 million across 5 years, with a median of $90.9 million in 2014.
  • Biggest five-year swings in Notes Payables: soared 16619.21% in 2013 and later crashed 97.21% in 2016.
  • Year by year, Notes Payables stood at $1.3 million in 2012, then skyrocketed by 16619.21% to $215.8 million in 2013, then crashed by 41.43% to $126.4 million in 2014, then crashed by 95.73% to $5.4 million in 2015, then tumbled by 83.33% to $900000.0 in 2016.
  • Business Quant data shows Notes Payables for UTHR at $900000.0 in Q2 2016, $5.4 million in Q1 2016, and $5.4 million in Q4 2015.